Development of asymptomatic pancreatitis with paradoxically high serum clozapine levels in a patient with schizophrenia and the CYP1A2*1F/1F genotype

Journal of Clinical Psychopharmacology

Volumn 30, Issue 6, 2010, Pages 737-739

  Sani, Gabriele ^a   Kotzalidis, Giorgio D ^a   Simonetti, Alessio ^a   Solfanelli, Andrea ^a   Mancinelli, Iginia ^a   Calabrò, Giusy ^a   De Rossi, Pietro ^a   De Luca, Ottavia ^a   Gentile, Giovanna ^a   Lionetto, Luana ^a   Manfredi, Giovanni ^a   Girardi, Nicoletta ^a   Ambrosi, Elisa ^a   Simmaco, Maurizio ^a   Tatarelli, Roberto ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CLOZAPINE; CYTOCHROME P450 1A2; DNA; HALOPERIDOL; INSULIN GLARGINE; INSULIN LISPRO; LORAZEPAM; NORCLOZAPINE; RISPERIDONE;

ADULT; AMYLASE BLOOD LEVEL; ANAMNESIS; ANTIBIOTIC THERAPY; CALCIUM BLOOD LEVEL; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECHOGRAPHY; FEMALE; GALLSTONE; GENOTYPE; HUMAN; HYPERGLYCEMIA; LETTER; MAGNETIC RESONANCE ANGIOGRAPHY; PANCREATITIS; PARANOID SCHIZOPHRENIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; CYTOCHROME P-450 CYP1A2; FEMALE; GENOTYPE; HUMANS; HYPERGLYCEMIA; PANCREATITIS; SCHIZOPHRENIA, PARANOID;

EID: 78649356711     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181faa7e3     Document Type: Letter

References (9)

1. Aitchison KJ, Jann MW, Zhao JH, et al. Clozapine pharmacokinetics and pharmacodynamics studied with Cyp1A2-null mice. J Psychopharmacol. 2000;14:353-359.
2. Linnet K, Olesen OV. Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes. Drug Metab Dispos. 1997;25:1379-1382.
3. Shin JG, Soukhova N, Flockhart DA. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos. 1999;27:1078-1084.
4. Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37: 243-265.
5. Aravagiri M, Marder SR. Simultaneous determination of clozapine and its N-desmethyl and N-oxide metabolites in plasma by liquid chromatography/ electrospray tandem mass spectrometry and its application to plasma level monitoring in schizophrenic patients. J Pharm Biomed Anal. 2001;26: 301-311.
6. Pfuhlmann B, Hiemke C, Unterecker S, et al. Toxic clozapine serum levels during inflammatory reactions. J Clin Psychopharmacol. 2009;29:392-394.
7. Greenwood-Smith C, Lubman DI, Castle DJ. Serum clozapine levels: a review of their clinical utility. J Psychopharmacol. 2003;17: 234-238.
8. Schmitz-Hübsch T, Schlaepfer TE, Westheide J, et al. Clozapine: acquittal of the usual suspect. World J Biol Psychiatry. 2009;10:981-984.
9. Raedler TJ, Hinkelmann K, Wiedemann K. Variability of the in vivo metabolism of clozapine. Clin Neuropharmacol. 2008;31: 347-352.